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Abstract 
 
Phytoestrogens are popular substances used in hormone replacement therapy due to 
their similar structure to estrogen and ability to interact like estrogens in the body. One 
particular phytoestrogen compound, genistein, has been observed to have an 
antiproliferative effect on breast cancer cells. The experiments investigated the effects of 
estrogen and genistein on the cells through MTS assays and PCNA immunoblots. The 
cell line demonstrated estrogen responsiveness through both assays, but results as to 
genistein’s effect on the T47D breast epithelial cells were inconclusive. 
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Introduction  
 
 The effects of hormone replacement therapy (HRT) and its association with 
increased cancer risks has recently been examined (Ross et al., 2000). Research supports 
that HRT does increase the risk for developing cancer (Holmberg et al., 2008). 
Therefore, many women have chosen to take over-the-counter phytoestrogens to treat 
the symptoms of menopause. It is suggested that since phytoestrogens have a similar 
structure to estrogen, they may act through the same pathways in the body to relieve 
the menopausal symptoms caused by the steep decrease in circulating estrogens. 
Phytoestrogens are often favored over HRT, because they are plant derived compounds 
viewed as healthier, natural alternatives that are widely available but unregulated.  
 The aim of this project was to observe the possible estrogenic or anti-estrogenic 
effects of the phytoestrogen, genistein, on a breast epithelial cancer cell line. It was 
hypothesized that the addition of genistein in a high estrogen environment would 
result in antiproliferative effects while the addition of the phytoestrogen at a low 
estrogen concentration would cause an increase in cell proliferation.  
An estrogen responsive cell line, T47D, was purchased from the ATCC with 
expressed estrogen receptors in order to test the effects of the addition of genistein to 
the cells. Several experimental conditions with different concentrations of genistein and 
estrogen provided inconclusive data, which did not support the hypothesis.  
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Background 
 
Breast cancer is the most common form of cancer affecting woman in the United 
States (Centers for Disease Control and Prevention, 2010). This has lead researchers to 
examine the major risk factors associated with the disease, as well as the differences 
between breast cancer rates of women in the United States as compared with women 
living in other countries. In particular, the rising risk of breast cancer is linked to the 
participation of premenopausal and postmenopausal women in hormone replacement 
therapies (HRT). 
The physical symptoms of menopause in premenopausal and postmenopausal 
women are often treated with HRTs, usually containing doses of estrogen and 
progesterone. The severe drop in the estrogen hormone due to menopause can produce 
a range of symptoms, including hot flashes, cold sweats, difficulty sleeping, and 
irritability (Dennerstein et al., 2000). These changes in the body can lead many women 
to make the choice to participate in HRT.  
However, studies have shown an increased risk of breast cancer as an HRT side 
effect (Holmberg, et al., 2008). A randomized study by L. Holmberg and H. Anderson 
was performed in 2002 with 442 Scandinavian, female, breast cancer survivors with 
follow-ups over a median of 4 years. The subjects were either administered hormone 
therapy or symptomatic management of menopausal symptoms without hormone 
addition. The women in the hormone therapy group developed twice as many new 
cancer events as the group receiving symptomatic management. The study concluded a 
statistical significance of increased risk of new breast cancer events in the hormone 
therapy group (Holmberg, et al. 2008).  
The rates of American women developing breast cancer are much higher than 
those of Asian women, with the risk for an American woman having been recorded as 
nearly seven times greater than the risk for an Asian woman (Bouker and Hilakivi-
Clarke, 2000). However, this discrepancy is mitigated as Asian women immigrate to the 
United States, which suggests that the increased risk factors are not based on genetic 
factors but are environmental (Wu, et al. 1996). A case study performed in 1986 
compared the estrogen plasma levels of premenopausal Caucasian woman living in 
Boston with plasma concentrations from woman born in various Southeast Asian 
countries and residing in Hawaii. The results found a thirty-two percent increase in 
estrogen plasma levels in premenopausal, Caucasian females living in the United States 
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(Goldin, et al., 1986). It can be proposed that the cancer rate discrepancy between 
American and Asian women may be caused by the difference in circulating estrogen 
levels in the body. 
Research has also found that Asian woman born in America have a sixty percent 
greater risk than Asian woman living in Asian countries of developing breast cancer, 
which again strengthens the argument of environmental factors contributing to the 
varied estrogen levels and breast cancer rates (Bouker and Hilakivi-Clarke, 2000). These 
environmental factors can be further narrowed down to the role of diet, as researchers 
have attributed dietary factors in contributing to half of recent breast cancer diagnoses 
(Bouker and Hilakivi -Clark, 2000). The consumption of soy is comparatively higher in 
Asian countries than the United States and is believed to be responsible for the cancer 
rates.  
Soy is often attributed as the dietary factor that reduces breast cancer rates 
among Asian females due to its high concentrations of many naturally occurring 
phytoestrogens, such as the isoflavones, genistein and daidzein (Ososki and Kennelly, 
2003).  Although research on daidzein is limited, the effect of genistein on cell 
proliferation has been examined.  
Phytoestrogens have a similar structure to estrogen, as shown in Figure 1, but are 
seen as safer, natural alternatives to estrogen therapies that originate from plants and 
non processed food products. In response to increasing criticism of HRTs and the rising 
rates of breast cancer, many women opt to pursue more natural remedies and choose 
over-the-counter phytoestrogen supplements to find relief for their menopause 
symptoms. Genistein is one such phytoestrogen, and is an active component in many 
over-the-counter products and supplements that aim to lessen the symptoms of 
menopause. These phytoestrogens are usually marketed as the ‘natural’ form of 
hormone replacement therapy.  
The exact pathway, in which phytoestrogens interact in the body, whether by 
mimicking estrogens or competitively blocking the estrogenic response, is not known 
(Warren and Devine, 2002). It is hypothesized that phytoestrogens act as estrogens at 
low concentrations and act to block estrogenic activity at high concentrations (Ososki 
and Kennelly, 2003).   
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Figure 1: Phytoestrogens, genistein, and 17β-estradiol structures (Wood et al., 2006) 
 
 
Estrogens are steroid hormones produced from cholesterol in the ovary, 
placenta, and adrenal cortex in the female body. Prior to menopause, the predominant 
estrogen, 17β-estradiol, is found in female circulation at a concentration of 40-400pg/mL. 
Post-menopause, estradiol is found at a concentration of 10-20 pg/mL (Anti Aging Guide, 
2010). This hormone functions at the higher, premenopausal levels to produce the 
secondary sex characteristics in women. Estrogen molecules diffuse into cells and bind 
to the domains of estrogen receptors (ERs), which are transcription factors activated by 
the estrogen hormone. 17β-estradiol binds specifically to either the ER α or ER β, which 
activates the transcription factors to modify gene transcription and possibly activate 
specific, mutated oncogenes to express tumor producing cells.  
Oncogenes are a family of genes responsible for normal development and tumor 
suppression in the body, but when mutated or overexpressed, can cause cancerous cell 
growth (Creighton, 1999). Estrogen is known to activate certain oncogenes, such as the 
inherited BRCA-1 and BRCA-2 genes, which are suspected to mutate and cause breast 
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cancer cell proliferation (Hilakivi-Clarke, 2000). This mode of ligand binding would not 
typically disrupt normal cell growth, but can cause cancerous cell growth when the 
genes activated are overexpressed, such as in the case of when women are exposed to 
high estrogen levels for long periods of time. It is believed that the longer the exposure 
to estrogen in the body, the greater the risk of developing cancer due to the hormone 
increasing expression and mutations in oncogenes. An early menarche and late 
menopause both foster environments of high estrogenic levels and activity for long 
periods of time to contribute towards an increased breast cancer risk (Clemons and 
Goss, 2001). The addition of the hormone post menopause, when natural estrogen levels 
have decreased, may therefore result in the activation or mutation of oncogenes to 
produce breast cancer (Kennemans and Bosman, 2003). 
One of the first major experiments relating estrogen production with breast 
cancer was performed by Beatson in 1896, in which the ovaries, a major source of 
estrogen synthesis, were removed from the bodies of patients suffering from breast 
cancer. This procedure yielded significant results and patients with the ovariectomies 
exhibited regression of the disease (Ali and Coombes, 2002).  These results have also 
been supported by recent experiments where the removal of ovarian estrogens in 
postmenopausal women produces a significant decrease in breast cancer development 
(Hilakivi-Clarke, 2000). Therefore, it can be concluded that exposure to estrogen can 
affect development and progression of breast cancer. However, not all breast cancers 
are responsive to estrogen. In a study by McGuire et al. in 2003, the level of estrogen 
responsive tumors was determined by measuring the final level of progesterone 
receptors (PgRs), which are indicated to be under the direct control of estrogen. PgRs 
were found in about 59% of metastatic breast cancer tumors with expressed estrogen 
receptors (McGuire et al., 2003). This signified that approximately 59% of estrogen 
receptors in metastatic tumors are responsive to estrogen and can respond to hormone 
therapy.   
Phytoestrogens are supplemented as an alternative to HRT and exhibit a high 
binding affinity for ER β. They are able to bind in a similar manner as estradiol and 
exhibit estrogenic effects, such as the increase in cellular transcription and proliferation 
(Bouker and Hilakivi-Clarke, 2000). Genistein is believed to exhibit a 20 to 30 fold 
greater binding affinity for ER β than ER α, but an overall 1,000 to 10,000 fold lesser 
binding affinity to either estrogen receptor when compared to the binding affinity of 
estradiol molecules (Kuiper et al., 1998).  Studies have also found that the ER β may 
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counteract the activity of ER α and act in an anti-proliferative manner (Strom et al., 
2003).Therefore, it is hypothesized that at higher estrogen concentrations, genistein may 
compete with 17β-estradiol for binding sites at the ER to prevent estrogenic activity and 
prevent overexpression or stimulation of mutated oncogenes. If the ER β does have anti-
proliferative effects as the research suggests, then the addition of phytoestrogens in a 
high estrogen environment will only decrease cell growth by altering the ratio of bound 
receptors in favor of the ER β. However, at low estrogen concentrations, when the ER is 
not saturated, genistein may only have an additive proliferative effect by introducing 
more bound phytoestrogens into the cell. Once again, this could be dangerous in terms 
of mutated oncogenes or overexpression of the genes it activates to possibly cause 
cancer. 
 Genistein is also theorized to exhibit antiproliferative effects through other non-
receptor mediated pathways, such as the inhibition of tyrosine kinase or topoisomerise 
II activity to possibly arrest cellular replication. These inhibitory mechanisms may 
result in increased cell apoptosis or decreased cell proliferation, with both mechanisms 
acting to reduce the growth of cancerous cells (Trock, et. al, 2006). 
In order to examine the affect of genistein at high and low estrogen conditions, it 
is necessary to find a breast epithelial cell line that exhibits estrogen responsiveness. 
This has proven a difficult task in previous Major Qualifying Projects (MQPs) where 
both the 2007 and 2008 studies of phytoestrogens on the MCF-7 cell line found the cell 
line to be unresponsive to estradiol (Raasumaa, 2008; DeVault, Kosmaczewski, and 
Tracy, 2009). This cell line was known to contain expressed estrogen receptors but the 
increased number of cell passages could have resulted in decreased sensitivity to 
estrogen (Pratt and Pollak, 1993). Due to the MCF-7 cells’ lack of estrogen 
responsiveness in previous MQPs, a new cell line was explored. The T47D breast 
epithelial line was originally obtained from the duct of the mammary glands in a 54 
year old female diagnosed with infiltrating ductal carcinoma. The cells were found to 
have expressed receptors for 17-β estradiol as well as several other steroids (ATCC, 
2010).  
These adherent cells of the T47D line were examined in our investigation under 
experimental conditions. It was necessary to demonstrate proof of concept by validating 
estrogen responsiveness in the new cell line. The cancerous breast cells were predicted 
to show increased proliferation in higher concentrations of estrogen, since the hormone 
when bound to the ER acts as a transcription factor to regulate cell growth. It was also 
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hypothesized that the phytoestrogen, genistein, would competitively inhibit estradiol 
binding to its receptor at high estrogen concentrations, but would exhibit estrogenic 
effects by binding to the ER receptor at low estrogen concentrations. These data could 
have significant implications in dietary recommendations and its associated breast 
cancer rates, as well as the regulation of over-the-counter phytoestrogen products.  
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Methodology 
 
Cell Cultures 
 
The T-47D breast epithelial cancer cell line was used throughout this project. This 
cell line was obtained from the American Type Culture Collection (ATCC) (Product # 
HTB-133). The ATCC is a private, nonprofit biological resource center and research 
organization that aims to provide biological products and services that further the 
specific objectives of research organizations, both public and private (ATCC, 2009). The 
T47D cell line has expressed receptors for estrogen, progesterone, and glucocorticoid. 
The doubling time for the cells was listed as 32 hours. However, handling of these cells 
in the lab showed the doubling time to be approximately between 28 hours to 32 hours. 
The cells were maintained in T75 flasks and in situations where there were too few cells 
to cultivate, the culture was initiated in a T25 flask. The cells were always incubated at 
37°C and 5% CO2. Based on the ATCC recommendations, the cells were cultured in 
RPMI-1640 growth medium (Sigma Aldrich, Catalog No. R8758), modified by adding 
10% Fetal Bovine Serum (FBS) (Thermo Scientific, Catalog No. SH303396.03), 1% 
Penicillin-Streptomycin Solution (Cellgro, Catalog No. 30-001-CI) and 0.2units/mg of 
Bovine Insulin (Sigma Aldrich, Catalog No. 11070-73-8). The cells were passaged upon 
reaching a confluency of >80%, and were split at different ratios based on the 
experiments being performed.  
 
Cell Passaging 
 
Cells were passaged according to the following protocol. The following steps are 
directed to a T75 flask of cells. The volumes of different solutions used for these steps 
were scaled down when cells were being passaged in T25 flasks. 
 
1. After removing the media from the flask, the cells were rinsed in 5mL Hank’s 
Balanced Salt Solution (Life Technologies, Catalog No. 14170-112) for 30 seconds. 
2. This was aspirated off and the cells trypsinized using 0.25% Trypsin (Gibco, 
Catalog No. 15050-065). About 2-3 mL of 0.25% trypsin was added and the flask 
incubated at room temperature for 2 to 3 minutes.  
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3. Upon getting 50% of the cells off the flask by visual inspection, 9mL of the 
culture media was added to the cells and after completely rinsing the flask 
bottom with the media; the cells were transferred into a 15mL centrifuge tube 
using a suitable pipette. 
4. The cells were centrifuged at 1000xg for 3 minutes to pellet them.  
5. After aspirating off the media, the cells were re-suspended in 4mL of fresh 
culture media. 
6. Using a hemocytometer, the cells were counted and further sub-cultivation ratios 
were decided. 
 
Assays 
 
MTS Assay 
 
In order to test for estrogen responsiveness, a cell proliferation assay was done. 
The Cell Titer 96®AQueous Non-Radioactive Cell Proliferation Assay was obtained from 
Promega (cat# G5421) to determine the cell proliferation of T47D cells in the presence of 
estrogen. The assay is composed of solutions of a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt; MTS] and an electron coupling reagent, phenazine ethosulfate (PMS).The 
MTS is reduced into a formazan product by living cells and can be measured directly at 
490nm. The MTS gets converted into formazan due to the dehydrogenase enzymes 
present in metabolically active cells. The higher the absorbance at 490nm, the higher the 
number of living cells in the culture. 
Cells were plated at 150,000 cells/well and 75,000 cells/wells in 24-well plates, in 
the RPMI growth media as described previously, for a time period of 48 hours. The 
RPMI media was then aspirated off and fresh media was added to each well. This fresh 
media consists of Dulbecco’s Modified Eagle Medium (DMEM) (Lonza, Catalog No. 12-
917F), which is absent of L-Glutamine or Phenol Red. To this media, 0.2 units/mg of 
insulin and  Dextran Charcoal Treated (DCT) 10% Fetal Bovine Serum (Hyclone, 
Catalog No. SH 30068.03) were also added. The cells were incubated in this modified 
media for an additional 24 hours. The DMEM media, which lacked Phenol Red, was 
used to minimize any false positive readings for estrogen receptors since Phenol Red, 
P a g e  | 15 
 
which is a pH indicator, is found to bind the estrogen receptors in human breast cancer 
cells MCF7. Even though a different cell line was used, this step was taken as a 
precautionary measure so as to be sure of observing actual results and not false 
positives, due to the reaction with Phenol Red.  A MTS Cell proliferation assay was 
started after a total growth time of 72 hours, which was run for 12 hours to measure cell 
proliferation. The cell proliferation was measured by adding 200 µl of the MTS assay 
solution to each well of 1ml cells, and running the assay for 12 hours before reading the 
absorbance values at 450nm. Several slight variations of this assay were run over the 
timeline of this project, to determine if the cells were responsive to different 
concentrations of estrogen which included 100µM, 10 µM, 1 µM, 0.1 µM and 0.01 µM. 
Some of these variations included plating a different set of cell densities, or switching 
from 24 well plates to 96 well plates and vice versa.  
One particular variation of this assay is the addition of 1% FBS instead of the 10% 
DCT FBS to the modified DMEM media, which is used to change the media of the cells 
after their initial growth period of 48 hours. This modification was performed to help 
cells stick to the bottom of the plate as opposed to the large clumps of cells floating in 
the cell media, and was hence incorporated into the assay method for future assays.  
The assays in the 96-well plates seemed to be failing consistently for no apparent 
reason but they could be attributed to the following reasons. There was very little 
working volume in 96-well plates (100 µl to 200 µl), which made it hard to maintain 
consistency of the number of cells added. Additionally, after performing a few 
experiments with different cell densities, it was still unclear what the best possible cell 
densities were to plate per well in a 96-well plate In order to overcome these issues, it 
was decided to switch to 24 well plates, since their working volumes are larger (1ml) 
and cell densities of 75,000 cells/well and 150,000 cells/well were plated.  
 
Immunoblotting 
 
A second approach, which consisted of immunoblotting, was chosen to 
demonstrate estrogen responsiveness in the cells and a few experiments were carried 
out using this approach. The immunoblot was performed using the PCNA antibody. 
PCNA or Proliferative Cell Nuclear Antigen is a protein that is mainly synthesized in 
the G1 and S phases of the cell cycle. It is involved in the DNA replication and aids the 
leading strand productivity during transcription (Santa Cruz Biotechnology, 2010). 
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Therefore, this protein was chosen as the target protein for the immunoblot process 
since cell proliferation is directly related to the amount of PCNA protein present in the 
cells. 
The cells were plated onto a 24-well plate and the following steps, similar to the 
MTS assay procedure were performed. The cells were plated at 150,000 cells/well and 
75,000 cells/wells in 24-well plates, and grown for a period of 48 hours in the modified 
RPMI growth media as described previously.  Five different concentrations of 17-β-
estradiol were prepared in the modified DMEM media with 1% FBS as described 
previously. These concentrations were 100 µM, 10 µM, 1 µM, 0.1 µM, 0.01 µM and 0 
µM.  When 48 hours of cell growth in the RPMI media elapsed, the RMPI media was 
aspirated off and 1ml of each estrogen concentration was added to the respective well 
of cells. After completing this step, the plate was left to incubate for an additional 24 to 
30 hours and then the plate was frozen down at -80°C, after aspirating off the DMEM 
media and rinsing the cells with 1% PBS.   
In order to perform the immunoblot, 12% acrylamide gels were cast. The 
protocols for this were taken from Current Protocols in Molecular Biology Vol.2, pages 
10.2.5 to 10.2.9 and 10.8.4 to 10.8.6 (Ausubel, et al.). There were a few changes made to 
the protocol as follows: 
For the separating and stacking gels, 40% Acrylamide was used instead of a 30% 
Acrylamide, mentioned in the protocol. Therefore, all the volumes of the other 
ingredients were scaled accordingly. Once the gels were prepared, the frozen cells were 
thawed and resuspended in 1%PBS, making sure as many of the cells were scraped off 
the bottom of the wells in the plate as possible, and resuspended in the solution. 
 
 
 
Immuno-analysis of the Protein Membrane 
 
The membrane was then processed through the immunodetection technique for 
PCNA antibody. The mouse monoclonal antibody PCNA (Santa Cruz Biotechnology 
Inc, Cat. No. sc 25280) was used as the primary antibody for the immuno-detection. 
This was diluted at 1:1500 in the blocking buffer. A goat anti-mouse IgG (Santa Cruz 
Biotechnology, Cat. No. sc 2008) was used as the secondary antibody in the detection.  
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Bradford Assay 
 
After the immunoblot, a Bradford assay was carried out to test for actual protein 
concentrations of the cell samples. A Coomassie (Bradford) Protein Assay Kit was used 
to perform the Bradford test (Thermo Scientific, Catalog No. 23200). The Bradford assay 
consisted of diluting each cell sample 50 fold in the provided Bradford Coomassie 
Reagent and reading absorbance values at 595nm in a spectrophotometer (Thermo 
Scientific, 2010). A standard curve was created using an Albumin BSA Standard (Piece, 
Catalog No. 1856269). The instructions for creating the different concentrations of the 
BSA standard were taken from the Instructions of Coomassie (Bradford) Protein Assay 
Kit (Thermo Scientific, 2010). The absorbance for the standard curve was also measured 
at 595nm and then a graph was plotted using the blank-corrected absorbance value of 
each BSA standard with its concentration in µg/ml. The standard curve was then used 
to determine the protein concentrations of the different cell samples.  
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Results 
 
MTS Assay Validation 
 
In order to validate the Cell Titer 96®AQueous Non-Radioactive Cell Proliferation Assay 
(MTS), cells were plated at 100,000, 50,000 and 25,000 cells/mL concentrations in 12 well 
plates. The cells were incubated in the modified RPMI media described in Methods for 
12 hours. This RPMI media was aspirated off and changed to the modified DMEM 
media detailed in the methods and the cells were incubated for another 12 hours. After 
a total of 24 hours incubation period, the MTS assay solution was added to the cells and 
the assay was run for 4 hours and the absorbencies of the cells were read on a 
spectrophotometer at 450nm. The microphotographs at 0, 12, and 24 hours after plating 
the cell concentrations are shown in Figure 2. The cell growth was visibly noticeable by 
different concentrations plated and increased with time incubated.  
 
 
  
P a g e  | 19 
 
Figure 2: Cell Growth Microphotographs 
 Time after plating T47D cells 
Cells/ 
mL 
0 hours   12 hours with media change   24 hours with media change 
100,000  
   
50,0000  
   
25,000  
   
 
 
Table 1: MTS Assay Validation Data 
 
Cell Concentration Plated (cells/mL) 
100,000 50,000 25,000 
0 (Assay 
Reagent Blank) 
Absorbance 
(450 nm) 
Assay Kit #1 0.842 0.762 0.717 0.174 
Assay Kit #2 0.775 0.727 0.671 0.196 
 
Assay Kit #1 = Promega CellTiter 96® AQueous One Solution Cell Proliferation - DOE = June 2010 (Cat # 
G3580) 
Assay Kit #2 = Promega CellTiter 96® Aqueous Non-Radioactive Cell Proliferation - DOE = March 2012 
(Cat # G5421) 
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The spectrophotometer readings from the plate are shown in Table 1.  The data exhibits 
a trend in increasing absorbance with increasing cell densities. However, these 
absorbance values are not for the specific cells numbers listed in Table 1. Almost 28 
hours had passed since the cells were first plated and this accounts for approximately 
one doubling time, which essentially means the absorbencies noted were for the cell 
densities of around 200,000 cells/well, 100,000 cells/well and 50,000 cells/well.  
 
The data in Table 1 was plotted in Figure 3.The curves show a positive relationship 
between absorbance and cell concentration for both assay kits. The R2 values are 
displayed on the graph and support the positive correlation.  
 
Figure 3: MTS Assay Validation Plots 
 
 
The Figure 3 shows the two different MTS assay kits used to demonstrate the MTS cell 
proliferation assay validation. Each plot shows a constant increase in absorbance values 
with an increase in the cell densities and is almost saturated since the cells are almost 
confluent.  
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Estrogen Responsiveness Assay using the MTS Kit 
 
Table 2 below shows the absorbance values of the formazan dye emitted from the cells 
during the MTS assay. These are results obtained 36 hours after the estrogen hormone 
was added to the cells.  
 
Table 2: Absorbance Values from MTS Assay for Different Cell Densities Plated at Different 
Estrogen Concentrations 
Cell Densities 10 µM 1 µM 0.1 µM 0.01 µM 0 µM Controls Remarks 
150K 2.821 2.469 2.521 2.614 2.593 2.303 Cells in media 
      0.794 No Cells 
75K 1.906 1.796 1.406 1.14 1.321   
      0.346 Assay Control Blank 
 
Table 2 shows the absorbance values measured at 450nm of the formazan dye in the 
cells for each of the estrogen concentrations. It is seen that for both the cell densities, the 
10 µM concentration of estrogen showed the highest absorbance values, which relates to 
a higher cellular proliferation rate. This data is plotted in Figure 4, in order to better 
visualize and draw conclusions. 
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Figure 4: Estrogen Responsiveness Plot: Absorbance versus Estrogen Concentrations  
 
Figure 4 above shows the two cell densities plotted at different estrogen concentrations. 
It is seen that the cell densities of 75,000 cells/well demonstrates estrogen 
responsiveness whereas the cell densities of 150,000 cells/well seems to decline with 
increasing concentrations of estrogen. This could be due to the fact that the cells at 
densities of 150,000cells/well reached confluence in the 72 hours of growth time plus 12 
hours of assay time and hence proliferation was inhibited.    
 
Immunoblotting 
After having obtained results from the MTS assay for estrogen responsiveness, a PCNA 
protein immunoblot was performed in order to both validate the results obtained with 
the MTS assay as well as show consistency in the results obtained. 
 
Table 3: Absorbance Values of Cells at the Different Estrogen Concentrations  
 Estrogen Concentrations 
Cell Densities 10 µM 1 µM 0.1 µM 0.01 µM 0 µM 
75K cells/well 0.712 0.754 0.628 0.773 0.702 
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Table 3 above shows the different absorbance values emitted by the formazan dye in the 
MTS assay at different estrogen concentrations for 75,000 cells/well. This data is plotted 
in Figure 5 to get a visual image, which shows inconclusive data since all the data 
points are very close to each other. Another duplicate set of cell samples taken from 
another plate as the samples in Table 3 were run on a SDS-PAGE to quantify cellular 
proliferation at different estrogen concentrations. A picture of the transferred 
membrane is seen in Figure 6.  
 
Figure 5: Absorbance Values for Cells at each Estrogen Concentration 
 
 
Figure 6: Immunoblot Bands for Concentrations of Estrogen 
 
Figure 6 shows the immunoblot obtained after processing it with the PCNA antibody. 
Faint bands appear that correspond to the different estrogen concentrations. These faint 
bands can be associated with too little protein having been loaded onto the gel. Figure 7 
below shows a peak analysis of the immunoblot in Figure 6 which shows that the 1 µM 
concentration of estrogen has the brightest band although all of the visible bands are 
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
0.900
0.01 0.1 1 10
A
b
so
rb
an
ce
 (
4
5
0
 n
m
)
Estrogen Concentration (µM)
Absorbance at 450nm for each estrogen concentration (µM)
P a g e  | 24 
 
very faint. Therefore nothing can be substantially concluded from the immunoblot and 
the data should be regarded as is observed. 
 
Figure 7: Different Immunoblot Band Intensities as Individual Peaks  
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Genistein Experiments 
 
Table 4 displays the proliferation effects of genistein added to cells cultured with 
varying estrogen concentrations, as measured by the MTS assay. From Table 4, the only 
effect of genistein is seen at 100 µM concentration of estrogen, which is an order of 
magnitude higher than the other values. Apart from this single data point, there 
appears to be no effect of either genistein or estrogen at lower concentrations of 
estrogen. Similarly, there is only a slight increase in absorbance values at 18.5 µM of 
genistein, at both 100 µM and 10 µM of estrogen. However, this data is again 
inconclusive since the effects of 100 µM estrogen have not been investigated previously.  
 
Table 4: Effects of Genistein at Varying Estrogen Concentrations (Genistein Experiment 1) 
 Estrogen Concentration (µM) 
Genistein 
Concentration 
(µM) 
100 10 1.0 0.1 0.0 
185.05 2.289 0.349 0.375 0.374 0.39 
18.5 0.634 0.465 0.361 0.517 0.372 
0 0.539 0.46 0.371 0.374 0.396 
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Figure 8: Absorbance Values of Genistein Treated Cells at Varying Estrogen Concentrations 
 
 
The genistein experiment described in Table 4 and Figure 8 was slightly modified and 
repeated, as can be seen in Table 5 and Figure 9. Additional estrogen concentrations 
were added and the individual genistein concentrations used were decreased, as shown 
in Table 5.  
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Table 5: Effect of Genistein at Varying Estrogen Concentrations (Genistein Experiment 2) 
 Estrogen Concentration (µM) 
Genistein Concentration (µM) 250  100  10  1  0.1  0.01  0  
50  1.169 1.063 1.400 1.202 1.605 1.611 1.614 
10  1.158 1.420 1.716 1.819 2.031 2.061 2.027 
1  1.671 1.366 1.809 1.468 1.882 1.901 2.198 
0 1.494 1.506 1.936 1.320 1.831 2.308 2.218 
 
From Table 5, it is seen that at 50 µM concentration of Genistein, there is a slight anti-
proliferative effect at every concentration of estrogen. However, it is not significant 
enough to conclude an anti-proliferative effect of genistein. Figure 9 shows the data in 
Table 5 as plotted on a logarithmic x-axis. In Figure 9, there is a steady decline of 
absorbance values for each genistein level, as the estrogen concentrations rise; however 
there is an unexpected spike at 10 µM concentration of estrogen that cannot be 
explained. Hence no trends can be drawn from this data and the interpretation of this 
data is difficult. 
 
Figure 9: Logarithmic Plot of Absorbance Values of Genistein Treated Cells at Varying 
Estrogen Concentrations 
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Bradford Assays for Protein Concentrations 
 
For the above Genistein experiments (Table 4), an immunoblot was also performed. 
However, at the end of the entire immunoblotting process (gel electrophoresis, transfer, 
primary antibody incubation, secondary antibody incubation, substrate detection), there 
were absolutely no bands visible on the membranes. In order to troubleshoot this 
incident, Bradford Assays were performed on the failed westerns for the different 
Genistein concentration samples to see if there was any protein in the actual samples 
themselves. The Bradford Assay Standards are displayed in Table 6 and the calculated 
protein concentrations for the different cell samples are in Table 7. 
 
Table 6: Albumin BSA Standards with Absorbance Values 
 
 
Table 6 above shows the concentration of the albumin standards used for creating a 
standard curve for the Bradford Assay. The absorbance values obtained were then used 
for creating a standard curve which is shown in Figure 10 below.  The equation of the 
line was obtained using a linear trend line and then the protein concentration values of 
each sample were obtained as seen in Table 7. 
Absorbance 
at 595nm 
Protein 
Concentrations 
(µg/ml) 
1.487 2000 
1.355 1500 
1.161 1000 
0.998 750 
0.847 500 
0.615 250 
0.556 125 
0.474 25 
0.464 0 
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Figure 10: Absorbance versus Protein Concentration 
 
 
Table 7: Calculated Protein Concentrations for Samples at Different Estrogen and Genistein 
Levels 
 100µM 10µM 1µM 0.1µM 0µM 
185.05 µM 284 51.1 60.9 57.1 64.7 
18.50 µM 41 56.3 66.3 44.5 55.6 
0 µM 291.4 65.5 163.2 60.9 67.9 
 
From Table 7, it is seen that there is a considerable amount of protein only in the 
samples where the estrogen concentration is at 100 µM and when the genistein 
concentration is either 185.05 µM or 0 µM. The middle concentration of 18.5 µM 
genistein does not show any significant protein concentration. Additionally, there is a 
spike in the protein concentration for 0 µM genistein and 1 µM estrogen concentration. 
This spike cannot be associated to any factors. These absorbance values translate into 
the amount of protein that was loaded onto each gel. 
 
 
y = 1757.6x - 842.44
-500
0
500
1000
1500
2000
2500
0 0.5 1 1.5 2
P
ro
te
in
 c
o
n
ce
n
tr
at
io
n
 (
µ
g/
m
l)
Absorbance (450 nm)
Absorbance vs. Protein concentration
µg/ml
Linear (µg/ml)
P a g e  | 30 
 
Discussion 
 
The MTS assay was used as the main technique for measuring cell proliferation 
throughout the experiment, apart from the immunoblotting technique that was 
performed on two occasions and in addition to the MTS assay. The MTS assay measures 
absorbance values at 450nm for the different samples, which are directly proportional to 
the amount of cells present. In order to use this assay to determine the proliferation of 
breast epithelial cancer cells in the presence of estrogen and genistein, the assay had to 
be validated. Table 1 contains the raw data obtained from the validation experiment, 
where the three cell densities plated were measured with the spectrophotometer. Figure 
3 shows the plot where the increase in absorbance readings is seen as directly 
proportional to the higher cell concentrations. The microphotographs in Figure 2 
provide visual evidence that the higher cell concentrations did actually contain a greater 
amount of cells, which the MTS assay in Figure 3 validated with readings of higher 
absorbance values. The microphotographs taken after 24 hours depict the confluency of 
the cells where the 100,000 cells/mL and 50,000 cells/mL concentrations of cells are 
observed as nearly confluent. This growth in the wells would have limited space and 
media available to cells to cause contact inhibition and prevent further cell proliferation. 
This would prevent the MTS assay from detecting any significant growth after 12 hours 
and could explain why the absorbance values measured appear to level between the 12 
hour and 24 hour time points. This may also explain why the validation of the MTS 
assay did not produce an ideal, linear proliferation curve.  
In addition, the initial cell densities plotted against the absorbance readings in 
Figure 3 do not reflect the final cell densities. The time elapsed for the experiment was 
24 hours and the doubling time for the cell line is approximately 28 hours to 32 hours, 
so the final concentrations would be closer to double the initial concentration. The 
experiment could have been repeated with lower cell concentrations to avoid 
confluence at 24 hours, but a positive correlation was still observed between absorbance 
readings and cell densities, thus validating the MTS assay. The two assay kits used were 
also compared. Both kits produced similar ranges of absorbance readings, supporting 
the validation of the MTS assay, but the assay kit #1, the one step MTS assay, was 
continued with for the rest of the experiments.  
The T47D cell line was found to be estrogen responsive during this experiment. 
Initially, there were issues with proving estrogen responsiveness in the T47D cell line. 
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This could have been due to several reasons. One reason is that there could potentially 
be problems with the estradiol stock solution being used. Halfway through the project, 
a new vial of 17-β-estradiol was bought and a new estrogen stock solution (100 mM) 
was prepared to carry out our experiments. The former estradiol stock was not labeled 
accurately and it was possible that solution was actually of a lesser concentration. If the 
concentration was 100 to 1000 fold less diluted than we believed, the cells would not 
have exhibited a strong estrogen response. Assuming that the estrogen stock was a 
reason behind the absence of measured estrogen sensitivity, it could also be suggested 
that the old stock was not as potent as a newly obtained stock solution, since the year it 
was purchased or opened was not labeled and the bottle was not stored appropriately. 
The new stock solution may have been relatively much more potent, which could 
explain the differences in measurements obtained. The purchase of a new estrogen 
stock solution may be the reason for the successful estrogen responsiveness 
experiments that were seen later during the project. 
Another problem could have been the addition of the DCT stripped FBS to the 
initial DMEM growth media. This was observed to be problematic to cell adhesion in 
the plates since replacing it with just FBS proved useful. DCT FBS helps to reduce 
serum concentration of endogenous hormones and growth factors such as estradiol that 
may interfere with the experimental process (Gemini Bio-Products, 2010). However, the 
DCT FBS could also reduce the lipids in the media that help the cells to plate down into 
the wells, which could have been a reason for no estrogen responsiveness.   
A final problem could have been that after several preliminary experiments, the 
ideal cell densities to be used were still not determined. The different cell densities used 
were 150,000 cells/well and 75,000 cells/well for a 24 well plate; and 75,000 cells/well, 
50,000 cells/well, 25,000 cells/well and 10,000 cells/well for a 96 well plate. These cell 
densities could have either reached confluence to shown no responsiveness beyond a 
certain cell population, or could have had very few cells in each well that they couldn’t 
survive and died off when transferred from the T75 flasks to the new environment of 
the plate wells.  
The Promega protocol recommended performing MTS assays with a starting cell 
concentration as low as 5,000 cells/well for a 96 well plate and 20,000 cells/well, for a 24-
well plate (Celltiter 96® aqueous, 2009). Although a much lower cell concentration was 
recommended for the MTS assay, we observed significant growth in Figure 4 in 24 wells 
plates with a concentration of 75,000 cells/well and chose to continue with this 
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concentration for the rest of the project. In addition, the microphotographs in Figure 2 
show that a concentration between 25,000 cells/well and 50,000 cells/well in a 12 well 
plate produced an appropriate amount of growth after 24 hours. In a 24 well plate, these 
ideal concentrations would translate to concentrations between 50,000 cells/well and 
100,000 cells/well. Therefore, the visual evidence of cell growth per well over a 24 hour 
period in Figure 2 supports the decision to continue experiments in a 24 well plate with 
a concentration of 75,000 cells/well.  
  The experiments performed demonstrated estrogen responsiveness in the cells. 
This can be observed in Table 2 and Figure 4. However, this was not consistent with 
different cell densities, mostly due to the fact that at higher cell densities of 150,000 
cells/well in a 24 well plate, the cells reached confluence during the growth period and 
were not able to grow properly in the wells due to contact inhibition. Hence, a cell 
density of 75,000 cells/well was chosen for the 24-well plates as the ideal number of cells 
since estrogen responsiveness was seen at that cell density and supported by the 
conclusions regarding confluence in Figure 1.  
After the T47D cell line was demonstrated as an estrogen responsive cell line, the 
phytoestrogen, genistein, was introduced as an experimental variable. Genistein was 
tested in both high and low estrogen concentrations to determine its effect on 
proliferation in the presence of estrogen. The inclusion of estrogen with the addition of 
genistein in the following experiments corresponded to the physiological conditions, 
since the human body has estrogen flowing at all times, albeit at different 
concentrations, depending on age, gender, and other factors. The first genistein 
experiment recorded in Table 4 found genistein to have an additive proliferative effect 
on cells. The curve in Figure 8 where no genistein was added had a final absorbance 
value of 0.539, while the curve with the greatest concentration of genistein, 185.05 µM, 
had a final absorbance of 2.289, both at a corresponding estrogen concentration of 
100µM. These results did not support our hypothesis that genistein would act as an 
inhibitory molecule at higher estrogen concentrations and exhibit estrogenic activity at 
lower estrogen concentrations.  
The unexpected results may be the result of incomplete saturation. If the 
estrogen receptors were not fully saturated, then the addition of phytoestrogens would 
cause the genistein molecules to bind to the ERs in a non competitive manner and may 
cause a proliferative effect (Ososki & Kennelly, 2003). However, the additive 
proliferative effect was not observed at the highest estrogen concentration, 100 µM, for 
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the 18.5 µM and 0 µM concentrations of genistein. This would suggest that the very 
concentrated 185.05 µM addition of genistein was the only factor differing from the 
other experimental groups and was the cause for the increased absorbance reading. If 
the ERs had not been fully saturated, then the control group with only estrogen would 
have measured increased proliferation, as well, for the higher estrogen concentrations.  
Another possibility for these results is that the genistein and estrogen bound only 
to the ER α and that the ER β may not have been expressed. It is hypothesized that the 
ER α stimulates proliferation while the ER β may act antagonistically and demonstrate 
anti-proliferative effects. If the ER β receptor was no longer expressed, which can occur 
in malignant cells of cancers, the hormone estradiol and genistein would only bind to 
the ER α to cause a binding preference of estradiol over genistein and an additive 
proliferative effect. This proliferation would be greatest at the highest concentration of 
estrogen and genistein, which was observed in Figure 8. However, it would be expected 
that the absorbencies for the estrogen control would also increase in a linear manner as 
the estrogen concentration increased, which was not shown in the absorbance values in 
Table 5. 
The reason for the high absorbance reading for the185.05 µM genistein is most 
likely due to the crystallization of the genistein. The phytoestrogen was not dissolved 
properly and crystallized in the media due to a high concentration After observing the 
inability for genistein to fully dissolve at that concentration, the remaining additions 
were heated and vortexed to ensure solubilization. The first addition at 100 µM 
estradiol was the exception and most likely absorbed the formazan dye from the MTS 
assay to read a much higher absorbance than the actual cell population would have 
measured.  
Research shows that genistein has anti-proliferative effects when in 
concentrations greater than 10 µM and proliferative at concentrations less than 10 µM 
(Bouker and Hilakivi-Clarke, 2000). It was decided to repeat the experiment and 
decrease the genistein concentration significantly so that it can dissolve in media. The 
initial genistein concentration of 185.05 µM was changed to 50 µM while the other 
concentrations were 10 µM, 1 µM, and 0 µM. 
The additive affects of genistein could also be linked to non estrogen mediated 
pathways. The aim of this project was to observe the effect of genistein based on the 
concentration of the estrogen environment, so any non ER mediated effects of genistein 
could not be studied thoroughly. 
P a g e  | 34 
 
The second genistein experiment produced data that differed greatly from the 
initial findings and supported the original hypothesis. The data in Table 5 supports the 
anti-proliferative effect of genistein at high estrogen concentrations and the estrogenic 
activity at low estrogen concentrations. Research suggests that genistein may be 
antiproliferative when in concentrations greater than 10 µM and proliferative at 
concentrations less than 10 µM (Bouker and Hilakivi-Clarke, 2000). This could be due 
the 1,000 to 10,000 fold greater affinity of 17β-estradiol compared to genistein in binding 
to an estrogen receptor (Kuiper et al.,1998). Higher concentrations of genistein may be 
necessary in order to competitively inhibit estradiol when estradiol is preferred by the 
receptor. This concept was supported by the data for the different genistein 
concentrations. The 50µM concentration of genistein showed a decrease in cell 
proliferation with higher estrogen levels, while the 10 µM genistein concentration began 
to increase at around a 250 µM estrogen concentration. The lesser concentrated 
genistein values, such as the 1.0 µM curve, demonstrated the greatest increase in slope 
at the highest estrogen concentration. The control curve of 0 µM genistein leveled off at 
250µM estrogen, which could indicate that the cells’ estrogen receptors were completely 
saturated.  However, the control value for the 0 µM estrogen concentration did not 
exhibit normal activity and demonstrated a similar curve to the data sets containing 
genistein. This control set should have shown estrogenic activity directly correlating 
cellular proliferation with estrogen concentration. It is possible that some form of 
contamination with genistein occurred which might have distorted the results or that 
similarly to the previous genistein experiment, only the ER α was expressed at such 
high estrogen concentrations.  
Overall, the results were not conclusive as to the exact activity or mechanism 
through which genistein acts. The preliminary genistein results also did not support our 
hypothesis, while the final experimental results did indicate a trend more supportive of 
genistein inhibition of estrogenic activity at high estrogen concentrations and showing 
estrogenic activity to increase cell proliferation at low estrogen concentrations. The 
wide-ranging results could indicate that genistein may be working through more than 
just the estrogen receptor mediated pathway as mentioned previously (Bouker and 
Hilakivi-Clarke, 2000). It is known that genistein also works through inhibiting tyrosine 
kinase activity and topoisomerase II activity (Bouker & Hilakivi-Clarke, 2000). This 
could possibly be the reason for our inconsistent findings throughout the course of this 
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project. Our findings necessitate further research and experiments to determine the 
action of the phytoestrogen, specifically genistein, on breast epithelial cancer cells. 
 All the variables in these experiments could be optimized and standardized in 
further projects. Starting with the cell densities, the MTS protocol recommended using 
lower, initial cell numbers. Closer adherence to this suggestion may provide more 
conclusive data, since the possibility of the MTS assay measuring lower absorbance 
values than expected could have been attributed to confluent cells inhibiting further 
growth. Additionally, a set range of estrogen concentrations need to be established, 
where it is proven that cells show a specific trend with increasing estrogen 
concentrations. A third variable that needs to be handled is the incubation times for 
cells between experimental conditions and also during them. Certain time course 
experiments could be performed to determine exact durations for experimental 
procedures. Furthermore, after the role of genistein is established in being 
antiproliferative to breast cancer cells, further investigations should be carried out with 
the other phytoestrogen compounds present in the different over-the-counter 
phytoestrogen supplements. 
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